The pioneers of Digital Therapeutics for Diabetes in South Asia, Wellthy Therapeutics disclosed the results of its several real-world studies that demonstrate remarkable improvements in patient health behavior and health outcomes coupled with enriched decision support for all healthcare stakeholders via largely added real-world clinical data. In fact, it was the 2nd consecutive time on July 30, 2018, for the firm to be a part of American Diabetes Association’s 78th Scientific Sessions in Orlando, Florida during which it unveiled these results and also the 11th time in being a part of major international conferences. This real-world study entailed around 102 patients utilizing the Wellthy Therapeutics’ Type II Diabetes patient app for 16 weeks besides their existing anti-diabetic drug prescription and also paramedical staff utilizing the Wellthy Therapeutics’ Type II Diabetes dashboard to monitor and intervene.
Eventually, patients witnessed an average drop of 1.17 percent in their HbA1c over and above the standard of care thereby surpassing the complementary effect of any other entry-level prescribed intervention. Moreover, almost 1,21,675 diabetes-related clinical & lifestyle data points generated from the study enhanced the paramedical capability to assist patients and improve outcomes while enabling AI of the Wellthy Therapeutics platform to provide real-time care to patients. This study supported by the Research Society for Diabetes in India and one of India’s largest private health insurers also metamorphosed the decision making of physicians by letting them deliver personalized care via better decision support and seamless patient clinical, lifestyle and behavioral journey data.
“Perfectly poised to bridge the gap of reliable patient journey data along with patient care between two consecutive visits, these studies deliver improved adherence, better patient satisfaction, and better outcomes,” elucidated Dr. Rajeev Chawla, President-Elect of the Research Society for the Study of Diabetes in India. “These studies illustrate the power of clinically validated digital therapeutics in encouraging healthy behavior amongst the patient population while giving the doctor requisite information to take better treatment decisions,” added Dr. Brij Makkar, Secretary of the Research Society for the Study of Diabetes in India. “The publishing of these studies in the ADA’s Diabetes Care this year exhibited a combination of standalone improvement in patient outcomes and decision support to physicians, which is indeed an effective real-world intervention to combat the growing burden of Type II diabetes in India and Asia”, asserted Abhishek Shah, Co-Founder & CEO of Wealthy Therapeutics.
Wellthy Therapeutics is a pioneering digital health company in chronic disease management via digital therapeutics platform that pledges to prevent, reverse and control the chronic illnesses of millions of patient lives. In fact, it outclasses as the first digital therapeutic for Type II diabetes that has been endorsed by Asia's largest diabetes association (RSSDI).
Read more news:
Fortinet Reminds Parents in India to Protect Children Online